River BioMedics develops human 3D cardiac models to mimic the human heart function in drug discovery and pre-clinical toxicity screenings

Pushing boundaries in bioengineering

River BioMedics is a biotech company aiming to create in vitro 3D human heart tissue for pre-clinical drug testing. Our target is to tackle the current issue of drug development: The rise in drug R&D costs and the decline in successful drugs reaching the market. Currently pharmaceutical companies spend a billion dollar figure on the development of a new drug entity, with a 90% chance of it failing to reach the market. The most common reason for failure during this developmental stage is drug induced cardiac toxicity. To solve this issue we develop 3D cardiac tissues, resembling the working human heart, for advanced drug discovery and toxicity screening using a multidisciplinary human stem cell-based approach.